Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: Recommendations of the Innovative Medicines Initiative ABIRISK consortium

Clinical and Experimental Immunology

Volumn 181, Issue 3, 2015, Pages 385-400

  Rup, B ^a   Pallardy, M ^b   Sikkema, D ^c   Albert, T ^d   Allez, M ^e   Broet, P ^b   Carini, C ^a   Creeke, P ^f   Davidson, J ^g   De Vries, N ^h   Finco, D ^a   Fogdell Hahn, A ⁱ   Havrdova, E ^j   Hincelin Mery, A ^k   Holland, M C ^c   Jensen, P E H ^l   Jury, E C ^m   Kirby, H ⁿ   Kramer, D ^o   Lacroix Desmazes, S ^b   Legrand, J ^p   Maggi, E ^q   Maillere B ^r   Mariette, X ^b   Mauri, C ^m   Mikol, V ^k   Mulleman, D ^s   Oldenburg, J ^d   Paintaud, G ^t   Pedersen, C R ^u   Ruperto, N ^v   Seitz, R ^w   Spindeldreher, S ^x   Deisenhammer, F ^y   more..

^a PFIZER INC   (United States)

^b INSERM   (France)

^c GLAXOSMITHKLINE   (United States)

^d UNIVERSITY HOSPITAL BONN   (Germany)

^e SAINT LOUIS HOSPITAL   (France)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g GLAXOSMITHKLINE   (United Kingdom)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j CHARLES UNIVERSITY   (Czech Republic)

^k SANOFI   (France)

^l UNIVERSITY OF COPENHAGEN   (Denmark)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁿ UCB PHARMA   (Belgium)

^o Institute of Drug Metabolism and Pharmacokinetics   (Germany)

^p IPSEN   (France)

^q UNIVERSITY OF FLORENCE   (Italy)

^r CEA SACLAY   (France)

^s UNIVERSITÉ DE TOURS   (France)

^t CNRS   (France)

^u NOVO NORDISK A S   (Denmark)

^v G GASLINI INSTITUTE   (Italy)

^w PAUL EHRLICH INSTITUT   (Germany)

^x NOVARTIS PHARMA AG   (Switzerland)

^y INNSBRUCK MEDICAL UNIVERSITY   (Austria)

more..

Author keywords

ABIRISK consortium; Anti drug antibodies; Biopharmaceuticals; Immunogenicity

Indexed keywords

BIOLOGICAL PRODUCT; BIOPHARMACEUTICAL AGENT; DRUG ANTIBODY; UNCLASSIFIED DRUG; NEW DRUG;

ANTIDRUG IMMUNE RESPONSE; ARTICLE; DRUG INDUSTRY; DRUG RESPONSE; DRUG SAFETY; HEALTH CARE ORGANIZATION; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; MEDICAL HISTORY; NOMENCLATURE; PATIENT MONITORING; POPULATION; PRIORITY JOURNAL; SCIENTIST; STUDY DESIGN; DRUG HYPERSENSITIVITY; IMMUNOLOGY; ORGANIZATION; ORGANIZATION AND MANAGEMENT; POLICY; PRACTICE GUIDELINE; STANDARD; STANDARDS;

ALLERGY AND IMMUNOLOGY; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; GUIDELINES AS TOPIC; HUMANS; ORGANIZATIONAL INNOVATION; ORGANIZATIONAL POLICY; REFERENCE STANDARDS; TERMINOLOGY AS TOPIC;

EID: 84939255213     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12652     Document Type: Article

References (76)

1. Dimitrov DS. Therapeutic proteins. Methods Mol Biol 2012; 899:1-26.
2. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008; 7:21-39.
3. Li J, Yang C, Xia Y et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98:3241-8.
4. McKoy JM, Stonecash RE, Cournoyer D et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008; 48:1754-62.
5. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010; 9:325-38.
6. Warrier I, Ewenstein BM, Koerper MA et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997; 19:23-7.
7. Wolbink GJ, Vis M, Lems W et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:711-15.
8. Bertolotto A, Sala A, Malucchi S et al. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psychiatry 2004; 75:1294-9.
9. Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. Am Assoc Pharm Sci J 2012; 14:296-302.
10. Garces S, Antunes M, Benito-Garcia E, da Silva JC, Aarden L, Demengeot J. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2014; 73:1138-43.
11. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013;72:165-78.
12. Collins PW, Chalmers E, Hart DP et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol 2013; 160:153-70.
13. Rosenberg AS, Worobec AS. A risk-based approach to immunogenicity concerns of therapeutic protein products. Part 1. Considering consequences of the immune response to a protein. Biopharm Int 2004; 17:22-6.
14. Rosenberg AS, Worobec AS. A risk-based approach to immunogenicity concerns of therapeutic protein products. Part 2. Considering host-specific and product-specific factors impacting immunogenicity. Biopharm Int 2004; 17.
15. Rosenberg AS, Worobec AS. A risk-based approach to immunogenicity concerns of therapeutic protein products. Part 3. Effects of manufacturing changes in immunogenicity and the utility of animal immunogenicity studies. Biopharm Int 2005; 18.
16. Ebbers HC, Crow SA, Vulto AG, Schellekens H. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol 2012; 30:1186-90.
17. Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 2011; 100:354-87.
18. Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S, Varki A. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol 2010; 28:863-7.
19. Mire-Sluis AR, Barrett YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004; 289:1-16.
20. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 2008; 48:1267-81.
21. Gupta S, Indelicato SR, Jethwa V et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 2007; 321:1-18.
22. Gupta S, Devanarayan V, Finco D et al. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J Pharm Biomed Anal 2011; 55:878-88.
23. Koren E, Smith HW, Shores E et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 2008; 333:1-9.
24. Buttel IC, Chamberlain P, Chowers Y et al. Taking immunogenicity assessment of therapeutic proteins to the next level. Biol J Int Assoc Biol Standard 2011; 39:100-9.
25. Shankar G, Arkin S, Cocea L et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. Am Assoc Pharm Sci J 2014; 16:658-73.
26. 26. Rituxan. US Prescribing information. 2014.
27. O'Mahony B, Noone D, Giangrande PL, Prihodova L. Haemophilia care in Europe - a survey of 35 countries. Haemophilia 2013; 19:e239-47.
28. West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 2010; 68:395-9.
29. European Medicines Agency (EMA). Guideline on the clinical investigation of recombinant and human plasma-derived factor IX products. Doc Ref. EMA/CHMP/BPWP/144552/2009. London, UK: EMA, 2012.
30. European Medicines Agency (EMA). Guideline on the clinical investigation of recombinant and plasma-derived FVIII products. Doc Ref. EMA/CHMP/BPWP/144533/2009. London, UK: EMA, 2012.
31. van Schie KA, Hart MH, de Groot ER et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 2015; 74:311-14.
32. Gneiss C, Tripp P, Ehling R et al. Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies. J Neuroimmunol 2006; 174:174-9.
33. Deisenhammer F, Reindl M, Berger T. Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b. J Interferon Cytokine Res 2001; 21:167-71.
34. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001; 115:807-11.
35. Ward ES, Ghetie V. The effector functions of immunoglobulins: implications for therapy. Ther Immunol 1995; 2:77-94.
36. Tatarewicz SM, Mytych DT, Manning MS, Swanson SJ, Moxness MS, Chirmule N. Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact. Bioanalysis 2014; 6:1509-23.
37. Moorehead PC, Thibeault L, Tuttle A et al. Rapid acquisition of immunologic tolerance to factor VIII and disappearance of anti-factor VIII IgG4 after prophylactic therapy in a hemophilia A patient with high-titer factor VIII inhibitor. J Pediatr Hematol Oncol 2015; 37:e220-2.
38. Lundkvist M, Engdahl E, Holmen C et al. Characterization of anti-natalizumab antibodies in multiple sclerosis patients. Mult Scler 2013; 19:757-64.
39. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007; 46:1828-34.
40. van Schouwenburg PA, Krieckaert CL, Nurmohamed M et al. IgG4 production against adalimumab during long term treatment of RA patients. J Clin Immunol 2012; 32:1000-6.
41. van Schouwenburg PA, Kruithof S, Votsmeier C et al. Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies. J Biol Chem 2014; 289:34482-8.
42. Gharagozlou S, Sharifian RA, Khoshnoodi J et al. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains. Thromb Haemost 2009; 101:834-9.
43. Chen X, Hickling T, Kraynov E, Kuang B, Parng C, Vicini P. A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics. Am Assoc Pharm Sci J 2013; 15:1141-54.
44. Kelley M, Ahene AB, Gorovits B et al. Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation. Am Assoc Pharm Sci J 2013; 15:646-58.
45. Vande Casteele N, Gils A et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013; 108:962-71.
46. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003;9:418-35.
47. Food and Drug Administration (FDA). FDA guidance for industry: assay development for immunogenicity testing of therapeutic proteins (draft guidance). Silver Spring, MD: FDA, 2009.
48. Food and Drug Administration (FDA). Guidance for industry: immunogenicity assessment for therapeutic protein products. Silver Spring, MD: FDA, 2014.
49. European Medicines Agency (EMA). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. Doc Ref. EMEA/CHMP/BMWP/14327/2006. London, UK: EMA, 2008.
50. European Medicines Agency (EMA). Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. Doc Ref. EMA/CHMP/BMWP/86289/2010. London, UK: EMA, 2012.
51. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346:469-75.
52. Rougeot C, Marchand P, Dray F et al. Comparative study of biosynthetic human growth hormone immunogenicity in growth hormone deficient children. Hormone Res 1991; 35:76-81.
53. Lofgren JA, Dhandapani S, Pennucci JJ et al. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J Immunol 2007; 178:7467-72.
54. Li J, Schantz A, Schwegler M, Shankar G. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet((R)) biolayer interferometry. J Pharm Biomed Anal 2011; 54:286-94.
55. Zhong ZD, Dinnogen S, Hokom M et al. Identification and inhibition of drug target interference in immunogenicity assays. J Immunol Methods 2010; 355:21-8.
56. Chen K, Page JG, Schwartz AM et al. False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assay. J Immunol Methods 2013; 394:22-31.
57. Rispens T, de Vrieze H, de Groot E et al. Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. J Immunol Methods 2012; 375:93-9.
58. Tatarewicz S, Miller JM, Swanson SJ, Moxness MS. Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics. J Immunol Methods 2010; 357:10-16.
59. Bendtzen K. Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists. Discov Med 2013; 15:201-11.
60. Gorovits B, McNally J, Fiorotti C, Leung S. Protein-based matrix interferences in ligand-binding assays. Bioanalysis 2014; 6:1131-40.
61. Wang Y-MC, Fang L, Zhou L, Wang J, Ahn H-Y. A survey of applications of biological products for drug interference of immunogenicity assays. Pharm Res 2012; 29:3384-92.
62. Llinares-Tello F, Rosas-Gomez de Salazar J, Senabre-Gallego JM et al. Practical application of acid dissociation in monitoring patients treated with adalimumab. Rheumatol Int 2014; 34:1701-8.
63. Patton A, Mullenix MC, Swanson SJ, Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods 2005; 304:189-95.
64. van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals 'hidden' immunogenicity in rheumatoid arthritis patients. J Immunol Methods 2010; 362:82-8.
65. Bloem K, van Leeuwen A, Verbeek G et al. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods 2015; 418:29-38.
66. Xue L, Fiscella M, Rajadhyaksha M et al. Pre-existing biotherapeutic-reactive antibodies: survey results within the American Association of Pharmaceutical Scientists. Am Assoc Pharm Sci J 2013; 15:852-5.
67. Xue L, Rup B. Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics. Am Assoc Pharm Sci J 2013; 15:893-6.
68. Calabresi PA, Giovannoni G, Confavreux C et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007; 69:1391-403.
69. Francis GS, Rice GP, Alsop JC, Group PS. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65:48-55.
70. Lentz SR, Misgav M, Ozelo M et al. Results from a large multinational clinical trial (guardian1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia 2013; 19:691-7.
71. Baert F, Drobne D, Gils A et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol 2014; 12:1474-81 e2; quiz e91.
72. Wang SL, Ohrmund L, Hauenstein S et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods 2012; 382:177-88.
73. Bartelds GM, Krieckaert CL, Nurmohamed MT et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305:1460-8.
74. Chen X, Hickling TP, Vicini P. A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 1-theoretical model. Pharmacometrics Syst Pharmacol 2014; 3:e133.
75. Chen X, Hickling TP, Vicini P. A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 2-model applications. Pharmacometrics Syst Pharmacol 2014; 3:e134.
76. Perez Ruixo JJ, Ma P, Chow AT. The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics. Am Assoc Pharm Sci J 2013; 15:172-82.